Conventional and combination topical photodynamic therapy for basal cell carcinoma: systematic review and meta-analysis

British Journal of Dermatology

Volumn 179, Issue 6, 2018, Pages 1277-1296

  Collier, N J ^a   Haylett, A K ^a   Wong, T H ^b   Morton, C A ^b   Ibbotson, S H ^c   McKenna, K E ^d   Mallipeddi, R ^e   Moseley, H ^c   Seukeran, D ^f   Ward, K A ^g   Mohd Mustapa, M F ^h   Exton, L S ^h   Green, A C ^a,i,j   Rhodes, L E ^a  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b Stirling Royal Infirmary   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d BELFAST CITY HOSPITAL   (United Kingdom)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^f JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^g ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^h BRITISH ASSOCIATION OF DERMATOLOGISTS   (United Kingdom)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD; ANTINEOPLASTIC AGENT; PHOTOSENSITIZING AGENT;

ADVERSE EVENT; BASAL CELL CARCINOMA; CANCER PATIENT; CRYOSURGERY; DISEASE CLEARANCE; DRUG EFFICACY; DRUG TOLERABILITY; EXCISION; HUMAN; LOW LEVEL LASER THERAPY; META ANALYSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SYSTEMATIC REVIEW; TOPICAL TREATMENT; TUMOR RECURRENCE; COMPARATIVE STUDY; EPIDEMIOLOGY; ESTHETICS; PAIN; PAIN MEASUREMENT; PATHOLOGY; PATIENT SAFETY; PHOTOCHEMOTHERAPY; PREVENTION AND CONTROL; PROCEDURES; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CRYOSURGERY; DOSE FRACTIONATION, RADIATION; ESTHETICS; HUMANS; IMIQUIMOD; NEOPLASM RECURRENCE, LOCAL; PAIN; PAIN MEASUREMENT; PATIENT SAFETY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 85052925090     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.16838     Document Type: Review

References (47)

1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166:1069–80.
2. Wu X, Elkin EE, Marghoob AA. Burden of basal cell carcinoma in USA. Future Oncol 2015; 11:2967–74.
3. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984; 10:1043–60.
4. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 2002; 147:41–7.
5. McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes. Arch Dermatol 1997; 133:593–6.
6. van Loo E, Mosterd K, Krekels GA et al. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer 2014; 50:3011–20.
7. Trakatelli M, Morton C, Nagore E et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol 2014; 24:312–29.
8. Clark CM, Furniss M, Mackay-Wiggan JM. Basal cell carcinoma: an evidence-based treatment update. Am J Clin Dermatol 2014; 15:197–216.
9. Morton CA, McKenna KE, Rhodes LE et al. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008; 159:1245–66.
10. Morton C, Szeimies RM, Sidoroff A et al. European Dermatology Forum Guidelines on topical photodynamic therapy. Eur J Dermatol 2015; 25:296–311.
11. Martin I, Schaarschmidt ML, Glocker A et al. Patient preferences for treatment of basal cell carcinoma: importance of cure and cosmetic outcome. Acta Derm Venereol 2016; 96:355–60.
12. de Haas ER. Treatment of choice in superficial basal cell carcinoma. Br J Dermatol 2015; 172:563.
13. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8:336–41.
14. Guyatt GH, Ebrahim S, Alonso-Coello P et al. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. J Clin Epidemiol 2017; 87:14–22.
15. Foley P, Freeman M, Menter A et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol 2009; 48:1236–45.
16. Wang I, Bendsoe N, Klinteberg CA et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144:832–40.
17. Basset-Seguin N, Ibbotson SH, Emtestam L et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18:547–53.
18. Szeimies RM, Ibbotson S, Murrell DF et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008; 22:1302–11.
19. Rhodes LE, de Rie M, Enstrom Y et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140:17–23.
20. Arits AH, Mosterd K, Essers BA et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14:647–54.
21. Roozeboom M, Arits A, Mosterd K et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. J Invest Dermatol 2016; 136:1568–74.
22. Jansen MHE, Mosterd K, Arits A et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. J Invest Dermatol 2018; 138:527–33.
23. de Haas ER, Kruijt B, Sterenborg HJ et al. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. J Invest Dermatol 2006; 126:2679–86.
24. de Vijlder H, Sterenborg H, Neumann H et al. Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. Acta Dermatovenereol 2012; 92:641–7.
25. Kessels J, Kreukels H, Nelemans PJ et al. Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolevulinic acid 20% versus two stage topical methylaminolevulinic acid: results of a randomized controlled trial. Br J Dermatol 2018; 178:1056–63.
26. Smucler R, Vlk M. Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med 2008; 40:153–8.
27. Haak C, Togsverd-Bo K, Thaysen-Petersen D et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas –a randomized clinical trial. Br J Dermatol 2015; 172:215–22.
28. Choi SH, Kim KH, Song KH. Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. J Eur Acad Dermatol Venereol 2016; 30:783–8.
29. Berroeta L, Clark C, Dawe RS et al. A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. Br J Dermatol 2007; 157:401–3.
30. Mosterd K, Thissen MR, Nelemans P et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol 2008; 159:864–70.
31. Rhodes LE, de Rie MA, Leifsdottir R et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143:1131–6.
32. Roozeboom MH, Aardoom MA, Nelemans PJ et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol 2013; 69:280–7.
33. Bath-Hextall FJ, Perkins W, Bong J et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007;1:CD003412
34. Zeitouni NC, Sunar U, Rohrbach DJ et al. A prospective study of pain control by a 2-step irradiance schedule during topical photodynamic therapy of nonmelanoma skin cancer. Dermatol Surg 2014; 40:1390–4.
35. Zeitouni NC, Paquette AD, Housel JP et al. A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. Lasers Surg Med 2013; 45:89–94.
36. Moseley H, Allen JW, Ibbotson S et al. Ambulatory photodynamic therapy: a new concept in delivering photodynamic therapy. Br J Dermatol 2006; 154:747–50.
37. Ibbotson SH, Ferguson J. Ambulatory photodynamic therapy using low irradiance inorganic light-emitting diodes for the treatment of non-melanoma skin cancer: an open study. Photodermatol Photoimmunol Photomed 2012; 28:235–9.
38. Kessels J, Dzino N, Nelemans PJ et al. Ambulatory photodynamic therapy for superficial basal cell carcinoma: an effective light source? Acta Derm Venereol 2017; 97:649–50.
39. Loebel N, Andersen R, Dawson T et al. Antimicrobial photodynamic therapy: a decade of development and clinical study. In: Photodynamic Medicine: From Bench to Clinic. London: Royal Society of Chemistry, 2016; 519–48
40. Bath-Hextall F, Nalubega S, Evans C. The needs and experiences of patients with skin cancer: a qualitative systematic review with metasynthesis. Br J Dermatol 2017; 177:666–87.
41. Kelleners-Smeets NW, Mosterd K, Nelemans PJ. Treatment of low-risk basal cell carcinoma. J Invest Dermatol 2017; 137:539–40.
42. Tinelli M, Ozolins M, Bath-Hextall F et al. What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial. BMC Dermatol 2012; 12:19.
43. Weston A, Fitzgerald P. Discrete choice experiment to derive willingness to pay for methyl aminolevulinate photodynamic therapy versus simple excision surgery in basal cell carcinoma. Pharmacoeconomics 2004; 22:1195–208.
44. Osiecka B, Jurczyszyn K, Ziolkowski P. The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma. Med Sci Monit 2012; 18:PI5–19
45. Zou Y, Zhao Y, Yu J et al. Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis. J Cosmet Dermatol 2016; 15:374–82.
46. Roozeboom MH, Arits AH, Nelemans PJ et al. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol 2012; 167:733–56.
47. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. British Association of Dermatologists. Br J Dermatol 1999; 141:415–23.